TABLE 2.

Summary of emtricitabine pharmacokinetic parameter estimates by age cohort following administration of emtricitabine oral solution and capsule formulations^a

Cohort and age	Dose and formulation	Cmax (μg/ml)	tmax (h)	AUC0-∞ (h · μg/ml)	t1/2 (h)	CL/F (ml/min)	CL/F (ml/min/1.73 m2)
2 (n = 2), 22-23	60 mg/m2, solution	1.02 ± 0.78	1.54 ± 0.65	4.81 ± 2.19	6.43 ± 0.21	137 ± 67	401 ± 184
mos	120 mg/m2, solution	1.51 ± 0.53	1.52 ± 0.66	8.13 ± 0.25	11.93 ± 1.11	140 ± 6	426 ± 15
3 (n = 8), 2-5 yrs	60 mg/m2, solution	1.13 ± 0.36	1.17 ± 0.60	4.32 ± 1.14	9.51 ± 2.53	174 ± 79	434 ± 158
	120 mg/m2, solution	1.99 ± 0.47	1.20 ± 0.54	7.70 ± 2.17	9.65 ± 2.71	196 ± 84	484 ± 139
2 + 3 (n = 10), 22	60 mg/m2, solution	1.11 ± 0.41	1.24 ± 0.60	4.42 ± 1.26	8.89 ± 2.58	167 ± 75	427 ± 153
mos-5 yrs	120 mg/m2, solution	1.90 ± 0.49	1.26 ± 0.54	7.79 ± 1.92	10.11 ± 2.60	185 ± 78	472 ± 125
4 (n = 8), 6-12 yrs	60 mg/m2, solution	1.06 ± 0.34	0.96 ± 0.66	4.45 ± 1.23	10.37 ± 2.85	254 ± 56	417 ± 118
	120 mg/m2, solution	1.91 ± 0.83	1.54 ± 1.13	8.02 ± 2.51	11.70 ± 2.30	288 ± 75	465 ± 126
	120 mg/m2, capsuleb	2.49 ± 0.87	1.85 ± 0.42	10.93 ± 3.49	10.17 ± 3.50	213 ± 60	338 ± 84
5 (n = 7), 13-17	60 mg/m2, solution	0.89 ± 0.26	1.61 ± 0.49	4.15 ± 0.75	9.29 ± 3.53	392 ± 90	427 ± 69
yrs	120 mg/m2, solution	1.55 ± 0.26	1.58 ± 0.53	8.45 ± 3.42	11.08 ± 2.17	406 ± 149	442 ± 119
	120 mg/m2, capsuleb	2.15 ± 0.53	1.32 ± 0.50	9.38 ± 3.03	10.77 ± 0.88	361 ± 139	387 ± 112

^aValues are means ± standard deviations.

^bn = 6 for the capsule formulation.